DTL and Ewing sarcoma: CDT2 (also known as DTL) overexpression is another recently identified biomarker of adverse prognosis in ES patients, and it was proposed that the ubiquitin ligase inhibitors may serve as therapeutic agents targeting CDT2 activity [46, 47].